Annals of Medicine
In the Pharmacology section of Annals of Medicine we consider for publication the latest advances in:
|Cardiovascular Pharmacology||Clinical Pharmacology||Experimental Pharmacology|
Annals of Medicine
Two-Year Impact Factor 3.243
Five-Year Impact Factor 3.840
Meet the Section Editor
Giuseppe Danilo Norata, Department of Pharmacological and Biomolecular Sciences (DiSFeB), University of Milan, Italy; Bassini Hospital, Cinisello Balsamo, Milan, Italy
Giuseppe Danilo Norata, Prof, MSc, PhD, is Full Professor of Pharmacology at the Department of Excellence of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy. He graduated in 1996 in Pharmacy, received the PhD in Experimental Medicine at the University of Siena in 2002 and was a post-doc from 2002 to 2004 at the Karolinska Institute in Stockholm, Sweden. His research activity is devoted to the investigation of molecular mechanisms involved in vascular and cardiometabolic diseases and their connection with immunometabolism from a translational perspective. He coordinates the activities at the Laboratory of Lipoproteins, Atherosclerosis and Immunity and those of the Laboratory of Cardiovascular Genetics and Genomics at the Center for The Study of Atherosclerosis at the Bassini Hospital. He has published more than 180 papers in the field of cardiovascular and immunometabolic diseases and has been speaker and/or chairmen in several international meetings. Giuseppe Danilo Norata is Associate Editor of Cardiovascular Research and of Atherosclerosis. He is co-chair of the European Atherosclerosis Society (EAS) Congress Committee, and a member of the Faculty of the International Atherosclerosis Research School and of the European Working Group on Immunometabolism.
Why is Annals of Medicine the Best Publication for Your Research?
Fully open access, general medical journal publishing articles under a CC BY license, allowing maximum sharing and reuse of articles to our international readership;
Publishing all scientifically valid research, including reporting of negative and null data, from translational to clinical research in all disciplines and therapy areas;
Led by an international editorial team of subject experts who ensure a constructive and rigorous peer review process;
Your research is promoted via a tailored, multi-channel approach to maximize visibility, readership and impact.